WO2007082726A3 - Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen - Google Patents

Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen Download PDF

Info

Publication number
WO2007082726A3
WO2007082726A3 PCT/EP2007/000375 EP2007000375W WO2007082726A3 WO 2007082726 A3 WO2007082726 A3 WO 2007082726A3 EP 2007000375 W EP2007000375 W EP 2007000375W WO 2007082726 A3 WO2007082726 A3 WO 2007082726A3
Authority
WO
WIPO (PCT)
Prior art keywords
leuprolide
neurodegenerative diseases
treating inflammation
flowable
containing composition
Prior art date
Application number
PCT/EP2007/000375
Other languages
English (en)
French (fr)
Other versions
WO2007082726A2 (de
Inventor
Christine Lemke
Original Assignee
Medigene Ag
Christine Lemke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Christine Lemke filed Critical Medigene Ag
Publication of WO2007082726A2 publication Critical patent/WO2007082726A2/de
Publication of WO2007082726A3 publication Critical patent/WO2007082726A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft die Verwendung einer Zusammensetzung, umfassend (a) einen biologisch abbaubaren thermoplastischen Polyester; (b) ein biokompatibles polares aprotisches Lösungsmittel, ausgewählt aus der Gruppe, bestehend aus einem Amid, einem Ester, einem Carbonat, einem Keton, einem Ether und einem Sulfonyl, wobei das biokompatible polare aprotische Lösungsmittel in wässrigem Medium oder Körperflüssigkeit mischbar bis dispergierbar ist, und (c) Leuprolid und/oder ein physiologisch verträgliches Salz oder Derivat davon zur Herstellung eines Medikaments zur Behandlung von entzündungsvermittelten neurodegenerativen Erkrankungen, insbesondere Alzheimerscher Erkrankung und/oder Parkinson-Syndrom.
PCT/EP2007/000375 2006-01-17 2007-01-17 Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen WO2007082726A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06000904 2006-01-17
EP06000904.0 2006-01-17

Publications (2)

Publication Number Publication Date
WO2007082726A2 WO2007082726A2 (de) 2007-07-26
WO2007082726A3 true WO2007082726A3 (de) 2007-10-04

Family

ID=38269010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/000375 WO2007082726A2 (de) 2006-01-17 2007-01-17 Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen

Country Status (1)

Country Link
WO (1) WO2007082726A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538999A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 緑膿菌感染症の治療における治療剤としてのバンド３タンパク質（８２４−８２９）および／またはメラニン細胞刺激ホルモン放出抑制因子の使用
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
EP0950403A2 (de) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsionen für in-situ Arzneistoffabgabesysteme
US6242421B1 (en) * 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
WO2002030393A2 (en) * 2000-09-21 2002-04-18 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
US6242421B1 (en) * 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
EP0950403A2 (de) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsionen für in-situ Arzneistoffabgabesysteme
WO2002030393A2 (en) * 2000-09-21 2002-04-18 Atrix Laboratories, Inc. Polymeric delivery formulations of leuprolide with improved efficacy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance

Also Published As

Publication number Publication date
WO2007082726A2 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2007082726A3 (de) Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen
WO2006084174A3 (en) Improved bioavailability and improved delivery of alkaline pharmaceutical drugs
EP2433655A3 (de) Homoarginin-Prodrugs von Amphetamin
HUP0302981A2 (hu) Javított hatékonyságú leuprolid polimeres bejuttatására szolgáló készítmények
WO2006052551A3 (en) Micromachined bilayer unit of engineered tissues
IL189008A (en) History of 1-Naphthalenyl-3-azabicyclo [0.1.3] hexane
WO2006094737A8 (en) Gastroresistant pharmaceutical formulations containing rifaximin
IL192670A (en) Carboxylic Acids of 1, 3-Dioxane, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication
MXPA06010592A (es) Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
EP2862581A3 (de) Verfahren, Verbindungen, Zusammensetzungen und Medien zur Abgabe von 3-Amino-1-Propanesulfonsäure
WO2005046576A3 (en) Magnetic ink tissue markings
WO2008134828A3 (en) Tissue degeneration protection
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
HK1131518A1 (en) Ornithine conjugates of amphetamine and processes for making and using the same
WO2004082628A3 (en) Improved bioavailability and improved delivery of acidic pharmaceutical drugs
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
CA2476267A1 (en) Multipart component for an orthopaedic implant
WO2006138515A3 (en) Surgical retractor extensions
WO2004064806A3 (en) Process for modifying drug crystal formation
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
WO2004067044A3 (en) Light-activated adhesive composite, system, and methods
WO2007118963A3 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
WO2007146085A3 (en) Creatine phosphate prodrugs, compositions and uses thereof
CN106471074A (zh) 用于施加药物递送聚合物涂料的方法和工艺

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07702829

Country of ref document: EP

Kind code of ref document: A2